179 related articles for article (PubMed ID: 29287062)
1. The influence of conjugation variables on the design and immunogenicity of a glycoconjugate vaccine against Salmonella Typhi.
Arcuri M; Di Benedetto R; Cunningham AF; Saul A; MacLennan CA; Micoli F
PLoS One; 2017; 12(12):e0189100. PubMed ID: 29287062
[TBL] [Abstract][Full Text] [Related]
2. Modulation of immune response and enhanced clearance of Salmonella typhi by delivery of Vi polysaccharide conjugate using PLA nanoparticles.
Meena J; Kumar R; Singh M; Ahmed A; Panda AK
Eur J Pharm Biopharm; 2020 Jul; 152():270-281. PubMed ID: 32470636
[TBL] [Abstract][Full Text] [Related]
3. First characterization of immunogenic conjugates of Vi negative Salmonella Typhi O-specific polysaccharides with rEPA protein for vaccine development.
Salman M; St Michael F; Ali A; Jabbar A; Cairns C; Hayes AC; Rahman M; Iqbal M; Haque A; Cox AD
J Immunol Methods; 2017 Nov; 450():27-33. PubMed ID: 28735760
[TBL] [Abstract][Full Text] [Related]
4. Immunization with the conjugate vaccine Vi-CRM₁₉₇ against Salmonella typhi induces Vi-specific mucosal and systemic immune responses in mice.
Fiorino F; Ciabattini A; Rondini S; Pozzi G; Martin LB; Medaglini D
Vaccine; 2012 Sep; 30(43):6111-4. PubMed ID: 22705173
[TBL] [Abstract][Full Text] [Related]
5. Determination of free polysaccharide in Vi glycoconjugate vaccine against typhoid fever.
Giannelli C; Cappelletti E; Di Benedetto R; Pippi F; Arcuri M; Di Cioccio V; Martin LB; Saul A; Micoli F
J Pharm Biomed Anal; 2017 May; 139():143-147. PubMed ID: 28282600
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the immunogenicity and biological activity of the Citrobacter freundii Vi-CRM197 conjugate as a vaccine for Salmonella enterica serovar Typhi.
Rondini S; Micoli F; Lanzilao L; Hale C; Saul AJ; Martin LB
Clin Vaccine Immunol; 2011 Mar; 18(3):460-8. PubMed ID: 21248155
[TBL] [Abstract][Full Text] [Related]
7. Physical and chemical characterization and immunologic properties of Salmonella enterica serovar typhi capsular polysaccharide-diphtheria toxoid conjugates.
Cui C; Carbis R; An SJ; Jang H; Czerkinsky C; Szu SC; Clemens JD
Clin Vaccine Immunol; 2010 Jan; 17(1):73-9. PubMed ID: 19889941
[TBL] [Abstract][Full Text] [Related]
8. The Vi conjugate typhoid vaccine is safe, elicits protective levels of IgG anti-Vi, and is compatible with routine infant vaccines.
Thiem VD; Lin FY; Canh DG; Son NH; Anh DD; Mao ND; Chu C; Hunt SW; Robbins JB; Schneerson R; Szu SC
Clin Vaccine Immunol; 2011 May; 18(5):730-5. PubMed ID: 21411598
[TBL] [Abstract][Full Text] [Related]
9. Short Vi-polysaccharide abrogates T-independent immune response and hyporesponsiveness elicited by long Vi-CRM
Micoli F; Bjarnarson SP; Arcuri M; Aradottir Pind AA; Magnusdottir GJ; Necchi F; Di Benedetto R; Carducci M; Schiavo F; Giannelli C; Pisoni I; Martin LB; Del Giudice G; MacLennan CA; Rappuoli R; Jonsdottir I; Saul A
Proc Natl Acad Sci U S A; 2020 Sep; 117(39):24443-24449. PubMed ID: 32900928
[TBL] [Abstract][Full Text] [Related]
10. A bivalent conjugate vaccine containing PspA families 1 and 2 has the potential to protect against a wide range of Streptococcus pneumoniae strains and Salmonella Typhi.
Kothari N; Kothari S; Choi YJ; Dey A; Briles DE; Rhee DK; Carbis R
Vaccine; 2015 Feb; 33(6):783-8. PubMed ID: 25545593
[TBL] [Abstract][Full Text] [Related]
11. Development of a bivalent conjugate vaccine candidate against malaria transmission and typhoid fever.
An SJ; Scaria PV; Chen B; Barnafo E; Muratova O; Anderson C; Lambert L; Chae MH; Yang JS; Duffy PE
Vaccine; 2018 May; 36(21):2978-2984. PubMed ID: 29681410
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials.
Bhutta ZA; Capeding MR; Bavdekar A; Marchetti E; Ariff S; Soofi SB; Anemona A; Habib MA; Alberto E; Juvekar S; Khan RM; Marhaba R; Ali N; Malubay N; Kawade A; Saul A; Martin LB; Podda A
Lancet Infect Dis; 2014 Feb; 14(2):119-29. PubMed ID: 24290843
[TBL] [Abstract][Full Text] [Related]
13. Preparation and evaluation of immunogenic conjugates of Salmonella enterica serovar Typhi O-specific polysaccharides with diphtheria toxoid.
Ali A; An SJ; Cui C; Haque A; Carbis R
Hum Vaccin Immunother; 2012 Feb; 8(2):189-93. PubMed ID: 22426380
[TBL] [Abstract][Full Text] [Related]
14. IgA and IgG1 Specific to Vi Polysaccharide of
Dahora LC; Jin C; Spreng RL; Feely F; Mathura R; Seaton KE; Zhang L; Hill J; Jones E; Alam SM; Dennison SM; Pollard AJ; Tomaras GD
Front Immunol; 2019; 10():2582. PubMed ID: 31781100
[TBL] [Abstract][Full Text] [Related]
15. Physico-chemical properties of Salmonella typhi Vi polysaccharide-diphtheria toxoid conjugate vaccines affect immunogenicity.
An SJ; Yoon YK; Kothari S; Kothari N; Kim JA; Lee E; Kim DR; Park TH; Smith GW; Carbis R
Vaccine; 2011 Oct; 29(44):7618-23. PubMed ID: 21843575
[TBL] [Abstract][Full Text] [Related]
16. Engineering, conjugation, and immunogenicity assessment of Escherichia coli O121 O antigen for its potential use as a typhoid vaccine component.
Wetter M; Kowarik M; Steffen M; Carranza P; Corradin G; Wacker M
Glycoconj J; 2013 Jul; 30(5):511-22. PubMed ID: 23053636
[TBL] [Abstract][Full Text] [Related]
17. Vi-Vaccinations Induce Heterogeneous Plasma Cell Responses That Associate With Protection From Typhoid Fever.
Cross DL; Verheul MK; Leipold MD; Obermoser G; Jin C; Jones E; Starr JS; Mohorianu I; Blohmke CJ; Maecker HT; Napolitani G; Hill J; Pollard AJ
Front Immunol; 2020; 11():574057. PubMed ID: 33424833
[TBL] [Abstract][Full Text] [Related]
18. Re-examination of immune response and estimation of anti-Vi IgG protective threshold against typhoid fever-based on the efficacy trial of Vi conjugate in young children.
Szu SC; Klugman KP; Hunt S
Vaccine; 2014 Apr; 32(20):2359-63. PubMed ID: 24630869
[TBL] [Abstract][Full Text] [Related]
19. Immune suppression induced by Vi capsular polysaccharide is overcome by Vi-DT conjugate vaccine.
An SJ; Yoon YK; Kothari S; Kim DR; Kim JA; Kothari N; Lee E; Park TH; Carbis R
Vaccine; 2012 Feb; 30(6):1023-8. PubMed ID: 22192846
[TBL] [Abstract][Full Text] [Related]
20. Specific and cross-reactive immune response to oral Salmonella Typhi Ty21a and parenteral Vi capsular polysaccharide typhoid vaccines administered concomitantly.
Pakkanen SH; Kantele JM; Savolainen LE; Rombo L; Kantele A
Vaccine; 2015 Jan; 33(3):451-8. PubMed ID: 25433216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
